Clinical Trial Update: Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of PCI-32765 in various B-cell malignancies completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia
• B-cell Diffuse Lymphoma
• B-cell Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• PCI-32765 (ibrutinib)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-05-07